权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Massachusetts Alzheimer's Disease Research Center

马萨诸塞州阿尔茨海默病研究中心

基本信息

批准号：
10378606
负责人：
BRADLEY T. HYMAN
金额：
$ 330.67万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-15 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10378606
关键词：
Alzheimer&apos s Disease Amyloid beta-Protein Authorization documentation Autopsy Basic Science Behavioral Biological Assay Biological Markers Blood Blood Vessels Cerebrospinal Fluid Clinical Clinical Data Clinical Research Clinical Sciences Clinical Trials Clinical Trials Design Cognitive Collaborations Communities Data Data Linkages Data Set Dementia Development Diagnosis Diagnostic Services Disease Education Environment Event Faculty Faculty Recruitment Fertilization Frontotemporal Dementia Functional disorder Future General Hospitals Goals Heterogeneity Image Imaging Techniques Impairment Individual Infrastructure Institution Knowledge Laboratories Leadership Learning Lesion Lewy Body Disease Link MRI Scans Marshal Massachusetts Measures Mentors Methods Mission Molecular Profiling Natural Immunity Nerve Degeneration Neurofibrillary Tangles Neuropsychology Participant Pathology Patients Phenotype Plasma Play Population Heterogeneity Positron-Emission Tomography Process Prognosis Research Research Methodology Research Personnel Research Support Resources Role Sampling Science Scientist Statistical Data Interpretation Structure Techniques Technology Testing Therapeutic Trials Training Training Programs Update Work base biomarker validation clinical biomarkers clinical center clinical phenotype cohort community setting digital disease heterogeneity education research follow-up frontotemporal degeneration imaging biomarker imaging study induced pluripotent stem cell inflammatory marker inter-individual variation medical schools mild cognitive impairment multidisciplinary neuroimaging neuropathology new technology next generation outreach posters programs racial and ethnic recruit resilience symposium targeted biomarker tau Proteins therapeutic evaluation therapeutic target tool validation studies

项目摘要

OVERVIEW: Massachusetts Alzheimer’s Disease Research Center (MADRC) The MADRC is an interdisciplinary Center at Massachusetts General Hospital, Harvard Medical School, with two major strategic goals: 1) to understand the underpinnings of heterogeneity of Alzheimer’s disease and Alzheimer’s Disease Related Disorders, and 2) to develop techniques, strategies, and technologies to accelerate a cure. To approach these goals, we propose 7 Cores (Administrative, Clinical, Biomarker, Imaging, Neuropathology, Data, and Outreach). We will use advanced Imaging, Biomarker, and analytic approaches to study our Research Cohort, which we view as a state of the art clinical phenotyping laboratory. Autopsy follow up for validation of biomarkers and imaging, and therapeutic targets, is essential. We plan to study a diverse population, both in the sense of various pathophysiologies, and also with varying racial and ethnic backgrounds, and rely on a vigorous ORE core both to fulfill our own recruitment needs and to support clinical trials and other affiliated programs. We have refocused our Center’s activities by remodeling the Research Cohort to include subjects who are cognitively normal, have mild cognitive impairment, or dementia, targeting diverse causes of dementia including Alzheimer’s disease and related disorders (Frontotemporal dementia, Lewy Body Disease, and vascular lesions). We postulate that heterogeneity of progression, even among individuals with the same “disease”, reflects underlying differences that can be uncovered, and that doing so will enhance clinical trial design by parsing variability from the very large, long cohort trials now in common use. Each Core is challenged to develop tools to help accelerate a cure – from intermediate imaging/biomarker targets that may help with diagnosis (a patient’s state) or prognosis (a patient’s fate), to performing autopsies to validate those targets. We will develop markers of inflammation and neurodegeneration, believing that innate immunity and resilience play a role in addition to tangles and plaques. Development of statistical and data methods are critical for anlaysis. These tools will allow us to test hypotheses about faster or slower rates of progression in a deeply phenotyped cohort. A final goal, central to our mission, is to build the future by training the next generation of scientists, which we propose to do under the framework of the Research Education Component. Together, we hope to make a difference in these devastating diseases.

概述：马萨诸塞州阿尔茨海默病研究中心（MADRC）